viewPolarean Imaging PLC

Polarean Imaging PLC - Polarean notes statement from Amphion Innovations

RNS Number : 5457N
Polarean Imaging PLC
25 September 2019

Polarean Imaging Plc 

("Polarean" or the "Company")


Polarean notes statement from Amphion Innovations


Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, notes the announcement made by its partner company, Amphion Innovations Plc ("Amphion") that Amphion has agreed to amend the terms of the Loan Facility with Amphion's debt provider ("the Lender"). 

The Lender has agreed to extend the maturity date of the Loan Facility to 30 September 2020.  No other terms have been amended.

The loan amount under the Facility will continue to be secured by the Amphion's pledge of 16,722,523 ordinary shares of Polarean. Amphion has transferred the legal title of the total pledged shares in Polarean to the Lender, but retains the beneficial interest in the shares.

Amphion holds 16,722,523 ordinary shares of Polarean, representing 14.61% of the issued share capital.


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.




Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com 

Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

Richard Morgan, Chairman 




SP Angel Corporate Finance LLP 

Tel: +44 (0)20 3470 0470  

David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance) 


Vadim Alexandre / Rob Rees (Corporate Broking)  



Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected] 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Polarean Imaging PLC

Price: 43.5

Market: AIM
Market Cap: £70.4 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Polarean Imaging in commercial launch mode for its lung function scanner

Polarean Imaging PLC's (LON:POLX) Richard Hullihen caught up with Proactive London's Andrew Scott following a recent pre-NDA meeting with the FDA. He says they're targeting the third quarter of this year to submit an NDA for its drug-device combination which uses hyperpolarised 129-Xenon gas...

on 19/6/20